---
layout: default
title: Anagrelide Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 48
evidence_level: L5
indication_count: 0
---

# Anagrelide Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Anagrelide Hydrochloride: Drug Repurposing Evaluation — Insufficient Evidence Pack

## One-Sentence Summary

Anagrelide hydrochloride is a platelet-reducing agent used for myeloproliferative disorders such as essential thrombocythemia. The current Evidence Pack contains **no TxGNN-predicted indications**, **no original indication records**, and **no safety data**, making a standard drug repurposing evaluation impossible at this time. All critical data gaps must be resolved before an assessment can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in this Evidence Pack |
| Predicted New Indication | None available |
| TxGNN Prediction Score | — |
| Evidence Level | — |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Safety Considerations

Please refer to the SmPC for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for anagrelide hydrochloride is critically incomplete across all evaluation dimensions — there are no TxGNN repurposing predictions, no original indication data, and no safety profile available. Without these foundational inputs, no repurposing candidate evaluation can be conducted.

**To proceed, the following is needed:**

- **\[DG001 — Blocking\]** Obtain TFDA package insert warnings and contraindications (download and parse the SmPC PDF from the TFDA website) to enable safety pre-screening
- **\[DG002 — High\]** Retrieve mechanism of action (MOA) from DrugBank API to support mechanistic relevance analysis
- Run TxGNN prediction pipeline for anagrelide hydrochloride to generate candidate indications
- Confirm active ingredient name normalization — verify whether "anagrelide hydrochloride" maps correctly to a DrugBank node (query log shows 1 result returned, but no DrugBank ID was captured)
- Investigate Taiwan regulatory status through TFDA to confirm whether the drug is actively under review or has never been submitted
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

